- Mercia Technologies said that Oxford Genetics, of which it owns 41%, had secured a 'multi-million pound' contract with a large global ecommerce provider of reagents and tools to the research and clinical community.

Oxford Genetics developed synthetic biology-based technologies for biologics discovery, development and delivery, with operations in the UK and US.

Mercia initially invested via its third-party managed funds before Oxford Genetics became a direct investment in December 2015.

'In the last 12 months the fast-growth biologics business has signed a number of out-licensing deals and agreements, and this deal is representative of a number of other high-value third-party contracts currently under discussion and negotiation,' Mercia said.

At 1:56pm: [LON:MERC] Mercia Technologies Plc share price was +0.8p at 29.6p

Story provided by